Writing Group Disclosures

Writing Group MemberEmploymentResearch GrantOther Research SupportSpeakers’ Bureau/HonorariaExpert WitnessOwnership InterestConsultant/Advisory BoardOther
Alan DaughertyUniversity of Kentucky Saha Cardiovascular Research CenterNIHNoneNoneNoneNoneNoneNone
Alan R. TallColumbia University MedicineNoneNoneNoneNoneNoneNoneNone
Mat J.A.P. DaemenAcademic Medical Center, Amsterdam, NetherlandsNoneNoneNoneNoneNoneNoneNone
Erling FalkAarhus University Hospital, DenmarkNoneNoneNoneNoneCoinventor of a patent related to genetically modified pigs as model for atherosclerosis*NoneNone
Edward A. FisherNew York University School of MedicineNIH; MerckNoneNoneMcDermott Will and Emery Law FirmNoneNoneNone
Guillermo García-CardeñaHarvard Medical School/Brigham and Women’s HospitalNoneNoneNoneNoneNoneNoneNone
Aldons J. LusisUniversity of California, Los AngelesNoneNoneNoneNoneNoneNoneNone
A. Phillip Owens IIIUniversity of CincinnatiNIHNoneNoneNoneNoneNoneNone
Michael E. RosenfeldUniversity of WashingtonNIHNoneNoneNoneNoneNoneNone
Renu VirmaniCVPath InstituteNoneNoneMerck*NoneNoneAbbott Vascular*; 480 Biomedical*; Medtronic*; W.L. Gore*; Surmodics*; Micel*None
  • This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be “significant” if (a) the person receives $10 000 or more during any 12-month period, or 5% or more of the person’s gross income; or (b) the person owns 5% or more of the voting stock or share of the entity, or owns $10 000 or more of the fair market value of the entity. A relationship is considered to be “modest” if it is less than “significant” under the preceding definition.

  • * Modest.

  • Significant.